Compare TG Therapeutics Inc (TGTX) vs Trade Desk Inc (TTD) Price & Performance

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

The Trade Desk (TTD) trades at $13.66, down 90% from its 2024 peak, with bearish technical signals and recent earnings misses. Revenue growth slowed to 3% in Q2 2026, and Q3 guidance projects a 12% decline. Despite strong profitability margins (net margin 13.6%), the stock faces execution challenges and advertiser pressure. Analyst sentiment is mixed with a $13.87 price target, while institutional selling and downgrades reflect mounting concerns.

Outlook remains cautious amid weak guidance and competitive threats, though current valuations (P/E 16.1) may attract value investors. Key risks include persistent revenue declines and market share erosion. Recovery hinges on stabilizing advertiser relationships and reversing recent execution gaps.